

# Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

*-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET --*

NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2025 financial results on Monday, November 3, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 3, 2025, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, <http://investors.karyopharm.com/events-presentations>. An archived webcast will be available on the Company's website approximately two hours after the event.

## **About Karyopharm Therapeutics**

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO<sup>®</sup> (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO<sup>®</sup>) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit [www.karyopharm.com](http://www.karyopharm.com), and follow us on [LinkedIn](#) and on X at @Karyopharm.

XPOVIO<sup>®</sup> and NEXPOVIO<sup>®</sup> are registered trademarks of Karyopharm Therapeutics Inc.

SOURCE Karyopharm Therapeutics Inc.

For further information: Brendan Strong, Senior Vice President, Investor Relations and Corporate Communications, 617.762.2661, [brendan.strong@karyopharm.com](mailto:brendan.strong@karyopharm.com)

---

<https://investors.karyopharm.com/2025-10-27-Karyopharm-to-Report-Third-Quarter-2025-Financial-Results-on-November-3,-2025>